X
<

Who's Watching TEVA Now?

PART:
1 2 3 4 5 6 7 8 9
Part 2
Who's Watching TEVA Now? PART 2 OF 9

Inside Teva Pharmaceutical’s 1H17 Performance

TEVA’s revenue trends

In 2016, Teva Pharmaceutical Industries (TEVA) reported revenues of ~$21.9 billion, or ~11% higher on a YoY (year-over-year) basis. In 1H17, TEVA reported revenues of ~$11.3 billion, compared with $9.8 billion in 1H16. In 2Q17, TEVA generated revenues of ~$5.7 billion, or ~13% higher YoY and 1% higher QoQ (quarter-over-quarter).

In 2Q17, TEVA in its GAAP (generally accepted accounting principles) results reported a net loss of ~$5.97 billion, compared with net income of ~$254 million in 2Q16, due to expenses from goodwill impairment charges of ~$6.1 billion. In 2Q17, the company reported a GAAP operating loss of ~$5.7 billion, compared with its net income of ~$361 million in 2Q16.

Inside Teva Pharmaceutical&#8217;s 1H17 Performance

Interested in TEVA? Don't miss the next report.

Receive e-mail alerts for new research on TEVA

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 2Q17, TEVA reported non-GAAP operating income of ~$1.59 billion, compared with $1.58 billion in 2Q16. In 2Q17, the company reported non-GAAP net income of ~$1.1 billion, compared with $1.2 billion in 2Q16. It reported non-GAAP EPS (earnings per share) of ~$1.02, compared with $1.25 in 2Q16.

1H17 and 2Q17 expenses

In 1H17, TEVA reported a cost of sales of ~$5.7 billion, compared with $4.2 billion in 1H16. In 1H17, the company reported R&D (research and development), S&M (selling and marketing), and G&M (general and administrative) expenses of ~$943 million, $1.9 billion, and $508 million, respectively, compared with $764 million, $1.79 billion, and $615 million in 1H16.

In 2Q17, TEVA reported a cost of sales of ~$2.9 billion, compared with $2.2 billion in 2Q16. In 2Q17, the company reported R&D, S&M, and G&M expenses of ~$486 million, 960 million, and $272 million, respectively, compared with $375 million, $952 million, and $311 million in 2Q16.

TEVA’s peers include Mylan (MYL), Novartis (NVS) (through Sandoz), Sun Pharmaceuticals, Pfizer (PFE) (through Hospira), Allergan, and Lupin. Notably, the iShares MSCI EAFE ETF (EFA) invests ~0.10% of its total portfolio holdings in TEVA.

X

Please select a profession that best describes you: